GlassScriptPhysician profile
John G Barron
NPI 1386738367
$3,580.16
in general payments reported to CMS, 2019-2025
20 companies · $794 in 2025
The $794 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $151 · 2021: $316 · 2022: $356 · 2023: $350 · 2024: $1,217 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $498.56 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $415.40 | 2022-2025 | Zenlens, Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $409.08 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $380.05 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $316.28 | 2019-2021 | |
| Oyster Point Pharma, INC. | $298.93 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $249.53 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $221.00 | 2019-2025 | Cequa |
| Alcon Vision LLC | $140.08 | 2023-2025 | Tryptyr, Rocklatan, Eysuvis |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Syfovre |
| Dompe US, INC. | $118.36 | 2024-2025 | Oxervate |
| Coopervision INC. | $104.94 | 2021-2023 | Myday Contact Lens |
| Allergan, INC. | $100.21 | 2020-2021 | |
| Glaukos Corporation | $45.93 | 2025 | Idosetr |
| Amgen INC. | $39.47 | 2024-2025 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34.93 | 2025 | |
| Rxsight INC | $23.90 | 2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $21.58 | 2023 | Tepezza |
| Harrow Eye, LLC | $20.54 | 2024 | Vevye, Natacyn |
| Shire North American Group INC | $16.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.